Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
07 Oct 2024
Historique:
received: 14 02 2024
revised: 26 06 2024
accepted: 12 08 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: ppublish

Résumé

Predicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion. Features of lymphoid tissue, including the formation of activated CD4+ T cell/B cell clusters and the emigration of matured plasmablasts, were recapitulated in the LO chip. Importantly, myeloid cells were competent at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of responses to mRNA vaccines. Comparison of on-chip responses to Wuhan monovalent and Wuhan/Omicron bivalent mRNA vaccine boosts showed equivalent induction of Omicron neutralizing antibodies, pointing at immune imprinting as reported in vivo. The LO chip thus represents a versatile platform suited to the preclinical evaluation of vaccine-boosting strategies.

Identifiants

pubmed: 39240335
pii: 276956
doi: 10.1084/jem.20240289
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
mRNA Vaccines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Vaccines, Synthetic 0
RNA, Messenger 0
Lipid Nanoparticles 0
Liposomes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Emulate
ID : S-RD21002
Organisme : Pasteur COVID-19 RP call
Organisme : Fondation de France
ID : PR-166156
Organisme : Institut Pasteur
ID : PFR7
Organisme : French Agency for AIDS and Emerging Diseases Research (ANRS-MIE)
ID : ECTZ213626
Organisme : Institut Carnot Pasteur Microbe & Santé

Informations de copyright

© 2024 Jeger-Madiot et al.

Auteurs

Raphaël Jeger-Madiot (R)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Delphine Planas (D)

Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Isabelle Staropoli (I)

Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Hippolyte Debarnot (H)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Jérôme Kervevan (J)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Héloïse Mary (H)

Biomaterials and Microfluidics Core Facility, Institut Pasteur, Université de Paris Cité , Paris, France.

Camilla Collina (C)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Barbara F Fonseca (BF)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.
Biomaterials and Microfluidics Core Facility, Institut Pasteur, Université de Paris Cité , Paris, France.

Rémy Robinot (R)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Stacy Gellenoncourt (S)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Olivier Schwartz (O)

Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Michael Bscheider (M)

Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland.

Samy Gobaa (S)

Biomaterials and Microfluidics Core Facility, Institut Pasteur, Université de Paris Cité , Paris, France.

Lisa A Chakrabarti (LA)

Control of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH